SCHEMBL20370415

SCHEMBL20370415

C=C(C)C(=O)Nc1ccc(C2CCC(CCCCC)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CYP2C9 P11712 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.42
▸ KMT2A Q03164 5/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ GAA P10253 2/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ HDAC3 O15379 1/20 0.39
▸ HDAC11 Q96DB2 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MITF O75030 2/20 0.38
▸ KLF5 Q13887 1/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ SLC18A3 Q16572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19854507 0.99 MAPT (0.46) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19856055 0.96 MAPT (0.44) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19856067 0.96 MAPT (0.44) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19854187 0.95 MAPT (0.44) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19855139 0.95 MAPT (0.44) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19856062 0.95 MAPT (0.44) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19856064 0.95 MAPT (0.44) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19854501 0.91 ALDH1A1 (0.56) MAPTALDH1A1LMNACYP2C9RXFP1
SCHEMBL19855940 0.87 MAPT (0.46) MAPTALDH1A1LMNACYP2C9KMT2A
SCHEMBL19854970 0.87 MAPT (0.39) MAPTALDH1A1LMNACYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 — — US disclosed
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2020-05-26 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195005-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE SP1, MBD2, PAXBP1 MAPT 1073/4885ALDH1A1 3826/4885LMNA 1840/4885
US-10662379-B2 Polymerizable polar compound, liquid crystal composition and liquid crystal display device SP1, MBD2, PAXBP1 MAPT 1073/4885ALDH1A1 3826/4885LMNA 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback